As the fourth leading cause of death in the U.S. and a leading cause of permanent disability, stroke has an incredible impact at both the individual and economic level. According to the CDC, an American dies every 4 minutes as the result of an acute stroke. With 87% of these strokes being ischemic in nature, rapid assessment and diagnosis of patients with stroke symptoms is required in order to ensure that eligible patients receive fibrinolytic therapy within the recommended time frame (around 3 hours). Research has shown that although healthcare providers in the inpatient setting are greatly reducing delays to treatment, there is still much work to be done in the pre-hospital setting to ensure that valuable time is not lost.
“If you are a mouse and suffer from depression, we can cure you!”. You may have heard similar statements for other diseases, which is a general reflection on the current state of drug development. After spending billions of dollars in pharmaceutical drug development only about 30 new drugs reached the market last year -- a number that is higher than in previous years, but still. It's not good news for patients, especially those suffering from mental illness, for whom the outlook on new drugs is even bleaker. Why the dry pipeline?
Nearly 30 million people worldwide are affected by the Alzheimer’s disease (AD) and the most recent estimates indicate that this number will quadruple within the next 40 years. The concern increases as AD is the leading cause of dementia, and, so far, there is no effective treatment to slow the progression or delay the onset of this malady.
Recovery from brain trauma like injury or a stroke is a complex process and one that is not yet under precise human control. More often than not, the process of resumption of blood flow to injured parts of the brain also creates additional damage. In addition to physical damage, exposure to extreme conditions like sub-zero temperatures as well as extremely hot conditions can also result in damage to neurons.
- Medical Marijuana – A Magic Bullet for Treating PTSD?